Visa Flags Hims & Hers Over Excessive Disputes on $149 Weight-Loss Subscriptions
Visa flags Hims for high dispute rates on $39-to-$149 weight-loss memberships. Company faces fees, scrutiny, and must lower rate for 3 months.
/ 83 items
#XY News-Driven Stocks↓
Buyout Chatter Lifts TG Therapeutics Shares — But No Deal Confirmed
Unconfirmed buyout speculation tied to Betaville surrounds TG Therapeutics, maker of BRIUMVI for multiple sclerosis. No official deal talks disclosed.
From Moderna to Sellas: The Next Major Catalyst in Cancer Vaccines
Sellas GPS data is imminent, Maxim keeps Buy/$30 PT. BNTX also in focus.
Wells Fargo and Stifel Flag Beneficiaries of Moderna-Merck Cancer Vaccine Data
Wells Fargo and Stifel say Moderna and Merck's Phase 3 cancer vaccine data could benefit Repligen, Danaher, Thermo Fisher, and Maravai LifeSciences. TEM stock is also surging.
B. Riley Keeps Buy on 4D Molecular After EyePoint’s Phase 3 Miss
4D Molecular gains support as B. Riley views EyePoint’s Phase 3 setback as favorable for its lead gene therapy candidate 4D-150.
Vera Therapeutics Shares Rally After Strong Interim eGFR Results Surface in FDA Review
FDA review papers reveal encouraging Week 52 eGFR findings (+5.2 placebo-adjusted) for TRUTAKNA in primary IgA nephropathy patients.